NCT04894227已完成4 期
A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac） in Health Adults Aged 26-45 Years
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 1,080
- 试验地点
- 1
- 主要终点
- Geometric mean titer(GMT) of neutralizing antibody to live SARS-CoV-2 in susceptible population
研究概览
简要总结
This study is a double-blind, randomized phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine (CoronaVac）manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to evaluate the lot-to-lot consistency, immunogenicity and safety of CoronaVac in healthy adults aged 26-45 years.
详细描述
This study is a double-blind, randomized phase Ⅳ clinical trial in healthy adults aged 26-45 years to evaluate the lot-to-lot consistency, immunogenicity and safety of the commercial-scale CoronaVac in healthy adults aged 26-45 years .The experimental vaccine was manufactured by Sinovac Research & Development Co.,Ltd. A total of 1080 healthy subjects aged 26 to 45 years old will be enrolled.The subjects will be randomly divided into three groups in a ratio of 1:1:1 to received two doses of vaccine on day 0 and day 28.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 26 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults aged 26-45;
- •The subjects can understand and voluntarily sign the informed consent form ;
- •Proven legal identity.
排除标准
- •Travel history / residence history of communities with case reports within 14 days prior to the study;
- •History of contact with a SARS-CoV-2 infection (positive in nucleic acid test) within 14 days prior to the study;
- •Have contacted patients with fever or respiratory symptoms from communities with case reports within 14 days prior to the study;
- •Two or more cases of fever and / or respiratory symptoms in a small contact area of volunteers, such as home, office etc. within 14 days prior to the study;
- •History of SARS-CoV-2 infection or receiving COVID-19 vaccine;
- •History of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema;
- •Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
- •Autoimmune disease (Systemic lupus erythematosus)or immunodeficiency / immunosuppression(HIV,history after organ transplantation)
- •Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc.;
- •Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
- •Thyroid disease or history of thyroidectomy, spleenlessness, functional spleenlessness, spleenlessness or splenectomy resulting from any condition;
- •Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;
- •Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
- •History of alcohol or drug abuse;
- •Receipt of blood products within in the past 3 months；
- •Receipt of other investigational drugs in the past 30 days；
- •Receipt of attenuated live vaccines in the past 14 days;
- •Receipt of inactivated or subunit vaccines in the past 7 days;
- •Onset of various acute or chronic diseases within 7 days prior to the study;
- •Axillary temperature >37.0°C;
- •Already pregnant (including a positive urine pregnancy test) or are breastfeeding, planning to get pregnant within 2 months;
- •The subjects participated in other clinical trials during the follow-up period, or will be planned within 3 months;
- •According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
结局指标
主要结局
Geometric mean titer(GMT) of neutralizing antibody to live SARS-CoV-2 in susceptible population
时间窗: Day 28 after the second dose
GMT of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose in susceptible population
次要结局
- GMT of the neutralizing antibody to live SARS-CoV-2 in total population(Day 28 after the second dose)
- GMI of the neutralizing antibody to live SARS-CoV-2 in susceptible population(Day 28 after the second dose)
- Seroconversion rate of the neutralizing antibody to live SARS-CoV-2 in total population(Day 28 after the second dose)
- Seroconversion rate of the neutralizing antibody to live SARS-CoV-2 in susceptible population(Day 28 after the second dose)
- Seropositive rate of the neutralizing antibody to live SARS-CoV-2 in susceptible population(Day 28 after the second dose)
- Seropositivity rate of the neutralizing antibody to live SARS-CoV-2 in total population(Day 28 after the second dose)
- Geometric mean increase (GMI) of the neutralizing antibody to live SARS-CoV-2 in total population(Day 28 after the second dose)
- Seroconversion rate of anti-SARS-CoV-2 S antibody(Day 28 after the second dose)
- Geometric mean concentration (GMC) of anti-SARS-CoV-2 S antibody(Day 28 after the second dose)
- Incidence of adverse reactions after vaccination(From the beginning of the vaccination to 28 days after the second dose)
- Seropositivity rate of anti-SARS-CoV-2 S antibody(Day 28 after the second dose)
- GMI of anti-SARS-CoV-2 S antibody(Day 28 after the second dose)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
4 期
Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 YearsCOVID-19NCT05112913Sinovac Research and Development Co., Ltd.2,520
Unknown
4 期
Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19COVID-19NCT05079217Sinovac Biotech Co., Ltd1,200
已完成
4 期
Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19COVID-19NCT05165966Sinovac Life Sciences Co., Ltd.340
已完成
2 期
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19COVID-19NCT05007496Aivita Biomedical, Inc.145
Unknown
4 期
Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy AdultsCOVID-19NCT04962308Sinovac Research and Development Co., Ltd.1,400